Genvec, Inc.

Cornell Research Foundation Inc.

Other

Merial Limited

Boehringer Ingelheim Animal Health USA Inc.

The Government of the United States of America, As Represented by the Secretary of Homeland Security

Jason Gall

Imre Kovesdi

Douglas E Brough

Duncan L McVey

Thomas J Wickham

Erik S Falck-Pedersen

Ronald G Crystal

Joseph T Bruder

Petrus W Roelvink

Damodar R Ettyreddy

Justin Widener

Lauri Motes-Kreimeyer

Marc Fiorucci

Leszlie Woodyard

Leonardo Siger

Christoph Kahl

Tom Burrage

Duncan Mcvey

Douglas Brough

The present invention encompasses FMDV vaccines or compositions. The invention encompasses recombinant vectors encoding and expressing FMDV antigens, epitopes or immunogens which can be used to protect animals, in particular ovines, bovines, caprines, or swines, against FMDV.

Recombinant adenovirus vectored FMDV vaccines and uses thereof

The invention provides methods for propagating a monkey adenovirus in a cell, including a human cell, comprising one or more gene products isolated from a human adenovirus. Also provided are methods for propagating wherein the monkey adenovirus comprises a nucleic acid sequence encoding a human adenovirus gene product. The invention further provides a monkey adenovirus, including a replication-deficient monkey adenovirus, obtained by such propagation methods.

Methods of propagating monkey adenoviral vectors

The invention provides methods for propagating a monkey adenovirus in a cell including a human cell, comprising one or more gene products isolated from a human adenovirus. Also provided are methods for propagating wherein the monkey adenovirus comprises a nucleic acid sequence encoding a human adenovirus gene product. The invention further provides a monkey adenovirus. including a replication-deficient monkey adenovirus, obtained by such propagation methods.

The invention provides a chimeric adenovirus fiber protein including a nonnative amino acid sequence, and a chimeric adenovirus fiber protein lacking a native amino acid receptor-binding sequence. The chimeric protein trimerizes when produced in a mammalian cell.

Chimeric adenovirus fiber protein

The present invention provides a chimeric adenoviral coat protein (particularly a chimeric adenovirus hexon and/or fiber protein). The chimeric adenovirus coat protein has a decreased ability or inability to be recognized by a neutralizing antibody directed against the corresponding wild-type adenovirus coat protein. The invention also provides an adenovirus comprising a chimeric adenovirus coat protein, and methods of constructing and using such an adenovirus, for instance, in gene therapy.

Nucleic acid that encodes a chimeric adenoviral coat protein

Chimeric adenoviral coat protein and methods of using same

A recombinant adenovirus comprising a chimeric fiber protein and a therapeutic gene, a method of gene therapy involving the use of such an adenovirus, and an adenoviral transfer vector for the generation of such a recombinant adenovirus are provided.

Chimeric adenoviral fiber protein and methods of using same

Growing community of inventors

Germantown, MD, United States of America

Jason Gall